6,7,8,9-Tetrahydro-5H-pyrimido<4.5-b>indol | 14707-14-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6,7,8,9-Tetrahydro-5H-pyrimido<4.5-b>indol
• 英文别名: 6,8-Diaza-1,2,3,4-tetrahydro-carbazol；6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]indole；5,6,7,8-Tetrahydro-9h-pyrimido[4,5-b]indole；6,7,8,9-tetrahydro-5H-pyrimido[4,5-b]indole
• CAS: 14707-14-3
• 化学式: C₁₀H₁₁N₃
• 分子量: 173.217
• InChiKey: FIODVZLXQCCQDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] LIM KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA LIM KINASE
  申请人：AMAKEM NV

  公开号：WO2015150337A1

  公开（公告）日：2015-10-08

  The present invention relates to new kinase inhibitors, more specifically LIM Kinase inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In particular, the present invention relates to new LIMK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and Prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said Compounds in the manufacture of a medicament for the application to a number of therapeutic indications including Ophthalmic and intestinal diseases.

  本发明涉及新的激酶抑制剂，更具体地是LIM激酶抑制剂，包括这种抑制剂的组合物，特别是制药品，以及这种抑制剂在治疗和预防疾病中的用途。具体来说，本发明涉及新的LIMK抑制剂，包括这种抑制剂的组合物，特别是制药品，以及这种抑制剂在治疗和预防疾病中的用途。此外，本发明涉及治疗方法和使用所述化合物制造药物的用途，适用于多种治疗适应症，包括眼科和肠道疾病。
• SUBSTITUTED PYRROLO[2,3-d]PYRIMIDINES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS
  申请人：Northwestern University

  公开号：US20160002252A1

  公开（公告）日：2016-01-07

  Disclosed are substituted pyrrolo[2,3-d]pyrimidine compounds. The disclosed compounds are shown to be useful in inhibiting the growth of cancer cell lines and treating cancer and cell proliferative disorders.

  公开了取代的吡咯并[2,3-d]嘧啶化合物。所公开的化合物被证明在抑制癌细胞系的生长和治疗癌症和细胞增殖性疾病方面是有用的。
• Aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino[2,3-b]indole and 5,6,7,8-tetrahydro-9H-pyrimidino[4,5-b]indole derivatives: CRF1 specific ligands
  申请人：Neurogen Corporation

  公开号：US20030105117A1

  公开（公告）日：2003-06-05

  Disclosed are compounds of the formula: 1 wherein Ar, R 1 , W, X and m are substituents as defined herein. These compounds are modulators of CRF receptors and are therefore useful for treating affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa or other feeding disorder, drug addiction, drug or alcohol withdrawal symptoms, inflammatory diseases, cardiovascular or heart-related diseases, fertility problems, human immunodeficiency virus infections, hemorrhagic stress, obesity, infertility, head and spinal cord traumas, epilepsy, stroke, ulcers, amyotrophic lateral sclerosis, hypoglycemia or a disorder the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF, in mammals, comprising: administering to the mammal a therapeutically effective amount of a compound of Formula I.

  本发明公开了以下式子的化合物 1 其中 Ar、R 1 、W、X 和 m 是本文定义的取代基。 这些化合物是 CRF 受体的调节剂，因此可用于治疗情感障碍、焦虑、抑郁、头痛、肠易激综合征、创伤后应激障碍、核上性麻痹、免疫抑制、阿尔茨海默病、胃肠道疾病、神经性厌食症或其他进食障碍、药物成瘾、药物或酒精戒断症状、炎症性疾病、心血管或心脏相关疾病、生育问题、人类免疫缺陷病毒感染、出血性应激反应、泌尿系统疾病和其他疾病、在哺乳动物中治疗可通过拮抗 CRF 起作用或促进作用的疾病，包括但不限于 CRF 诱导或促进的疾病，包括： - 给哺乳动物注射一种治疗 CRF 的药物，该药物可通过拮抗 CRF 起作用或促进作用：向哺乳动物施用治疗有效量的式Ⅰ化合物。
• US6291473B1
  申请人：——

  公开号：US6291473B1

  公开（公告）日：2001-09-18
• US6472402B1
  申请人：——

  公开号：US6472402B1

  公开（公告）日：2002-10-29